logo
Deepak Fertilisers, PCL sign long-term regasification pact with Petronet LNG

Deepak Fertilisers, PCL sign long-term regasification pact with Petronet LNG

Deepak Fertilisers & Petrochemicals Corporation, along with its step-down subsidiary Performance Chemiserve (PCL), has entered into a long-term regasification agreement with Petronet LNG (PLL), India's leading LNG infrastructure company.
Under the terms of the agreement, Petronet LNG will regasify approximately 25 TBTUs of LNG annuallyafter an initial ramp-up periodprimarily at its Dahej terminal. The regasified gas will be supplied mainly to Deepak Fertilisers and PCLs manufacturing units in Taloja for internal consumption.
According to an exchange filing, the contract will be executed over a period of five years.
This agreement will help the company and PCL ensure the logistical and commercial arrangements required to receive imported LNG at their manufacturing facilities via the existing national gas grid in Taloja, Mumbai, supporting the delivery of their integrated gas-to-ammonia-to-chemicals value chain strategy.
With this last-mile regasification contract, the company said it would be strategically positioned to deliver a full value chainfrom gas to ammonia to building-block nitric acid and further downstream to products such as NPK fertilizers, industrial chemicals, and mining chemicals. The company emphasized that its forward integration journey toward delivering customised solutions and specialised products would gain further foundational strength from this end-to-end arrangement. It also expects this tie-up to support a risk-mitigated and value-accretive product portfolio aligned with India's long-term growth story.
Deepak Fertilisers and Petrochemicals Corporation (DFPCL) is among the Indias leading manufacturers of industrial chemicals and fertilisers. With a strong presence in technical ammonium nitrate (mining chemicals), industrial chemicals and crop nutrition (fertilisers), the company supports critical sectors of the economy such as infrastructure, mining, chemicals, pharmaceutical and agriculture.
Petronet LNG was formed to develop, design, construct, own, and operate liquefied natural gas (LNG) import and regasification terminals in India.
Shares of Deepak Fertilisers and Petrochemicals Corporation rose 0.01% to Rs 1,580, while shares of Petronet LNG declined 1.72% to Rs 300.05 on the BSE.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Emcure Pharmaceuticals reports 41% surge in Q1 net profit driven by strong domestic and international growth
Emcure Pharmaceuticals reports 41% surge in Q1 net profit driven by strong domestic and international growth

Economic Times

timean hour ago

  • Economic Times

Emcure Pharmaceuticals reports 41% surge in Q1 net profit driven by strong domestic and international growth

Emcure Pharmaceuticals reported a strong first quarter with a 41% increase in net profit, reaching Rs 215 crore, and a 16% rise in revenue to Rs 2,101 crore. Growth was fueled by robust domestic and international performance, particularly in the rest of the world and Canada. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Pune-based Emcure Pharmaceuticals on Thursday reported a 41% year-on-year increase in first quarter net profit at Rs 215 from operations rose 16% to Rs 2,101 crore, driven by robust performance in domestic and international businesses. The company's EBITDA margins for April-June stood at 19.2% with EBITDA up 20.1% YoY. International business grew 22%, while the rest of the world business grew 42%. The company's Canada business grew 16.4% led by new launches and market share gains. Europe saw early benefits of new launches and grew 12.8%.'We continue to augment our portfolio in all our focus markets through in-licensing and in-house development,' said Satish Mehta, CEO and managing director, Emcure Pharmaceuticals Its domestic business grew 9.4% led by strong performance in all out key therapies and aided by new initiatives in derma and the quarter, the company strengthened its domestic business through expansion of its strategic partnership with Sanofi. Going forward, Emcure will be marketing and distributing Sanofi's oral anti-diabetic portfolio in addition to the cardiovascular portfolio.'The expanded Sanofi partnership positions us well in the fast-growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets, which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins,' Mehta of Emcure Pharmaceuticals closed 1.58% lower at Rs 1,398.80 apiece on the BSE on Thursday. The company announced the earnings during market hours.

Emcure Pharmaceuticals reports 41% surge in Q1 net profit driven by strong domestic and international growth
Emcure Pharmaceuticals reports 41% surge in Q1 net profit driven by strong domestic and international growth

Time of India

timean hour ago

  • Time of India

Emcure Pharmaceuticals reports 41% surge in Q1 net profit driven by strong domestic and international growth

Pune-based Emcure Pharmaceuticals on Thursday reported a 41% year-on-year increase in first quarter net profit at Rs 215 crore. Revenue from operations rose 16% to Rs 2,101 crore, driven by robust performance in domestic and international businesses. The company's EBITDA margins for April-June stood at 19.2% with EBITDA up 20.1% YoY. International business grew 22%, while the rest of the world business grew 42%. The company's Canada business grew 16.4% led by new launches and market share gains. Europe saw early benefits of new launches and grew 12.8%. 'We continue to augment our portfolio in all our focus markets through in-licensing and in-house development,' said Satish Mehta, CEO and managing director, Emcure Pharmaceuticals. Its domestic business grew 9.4% led by strong performance in all out key therapies and aided by new initiatives in derma and OTC. During the quarter, the company strengthened its domestic business through expansion of its strategic partnership with Sanofi. Going forward, Emcure will be marketing and distributing Sanofi's oral anti-diabetic portfolio in addition to the cardiovascular portfolio. 'The expanded Sanofi partnership positions us well in the fast-growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets, which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins,' Mehta said. Shares of Emcure Pharmaceuticals closed 1.58% lower at Rs 1,398.80 apiece on the BSE on Thursday. The company announced the earnings during market hours.

BSE Q1 profit doubles to Rs 538 cr; revenues cross Rs 1,000-cr mark
BSE Q1 profit doubles to Rs 538 cr; revenues cross Rs 1,000-cr mark

News18

time2 hours ago

  • News18

BSE Q1 profit doubles to Rs 538 cr; revenues cross Rs 1,000-cr mark

New Delhi, Aug 7 (PTI) Leading stock exchange BSE on Thursday reported a more than two-fold jump in net profit to Rs 538 crore for the quarter ended June 2025 compared to Rs 264 crore in the corresponding period last year. The exchange posted record quarterly revenues of Rs 1,044 crore in the April-June quarter of FY26, a sharp 56 per cent increase from Rs 668 crore in the first quarter ended June 30, 2024, BSE said in a statement. During the quarter, BSE's equity derivatives segment recorded a total of 498 crore contracts traded, generating Rs 598 crore in revenue. Transactions on the BSE StAR MF platform grew by 30 per cent year-on-year to 18.3 crore in Q1 FY26, up from 14.1 crore in the same period last year. The platform's market share stood at 89 per cent. PTI SP MR First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store